Emergency Department Visits for Nonfatal Opioid Over Across Six US Health Care Systems

Annals of Emergency Medicine 79, 158-167 DOI: 10.1016/j.annemergmed.2021.03.013

Citation Report

#	Article	IF	CITATIONS
1	Impact of COVID-19 on opioid use in those awaiting hip and knee arthroplasty: a retrospective cohort study. BMJ Quality and Safety, 2023, 32, 479-484.	3.7	16
2	The impact of the national stay-at-home order on emergency department visits for suspected opioid overdose during the first wave of the COVID-19 pandemic. Drug and Alcohol Dependence, 2021, 228, 108977.	3.2	19
3	Using a "Big Events―framework to understand emergency department use among women experiencing homelessness or housing instability in San Francisco during the COVID-19 pandemic. International Journal of Drug Policy, 2021, 97, 103405.	3.3	6
4	Tele-buprenorphine for emergency department overdose visit follow up and treatment initiation. American Journal of Emergency Medicine, 2021, 50, 409-412.	1.6	3
5	"How can I hug someone now [over the phone]?†Impacts of COVID-19 on peer recovery specialists and clients in substance use treatment. Journal of Substance Abuse Treatment, 2021, 131, 108649.	2.8	5
6	Moving Upstream: A Social Emergency Medicine Approach to Opioid Use Disorder. Annals of Emergency Medicine, 2022, 79, 168-171.	0.6	1
7	Emergency department care for patients who use opioids during the COVID-19 pandemic. Canadian Journal of Emergency Medicine, 2022, 24, 123-125.	1.1	1
8	Nonfatal opioid overdoses before and after Covid-19: Regional variation in rates of change. PLoS ONE, 2022, 17, e0263893.	2.5	7
9	Disparities in Emergency Department Visits for Opioid and Stimulant Overdoses in Florida During COVID-19. Population Health Management, 2022, 25, 480-486.	1.7	1
10	Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. Annals of Emergency Medicine, 2022, 79, 441-450.	0.6	8
11	Opioid usage and COVID-19 prognosis: A systematic review and meta-analysis. American Journal of Emergency Medicine, 2022, 56, 51-56.	1.6	11
12	Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot. Prehospital Emergency Care, 2023, 27, 334-342.	1.8	3
13	Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities. Substance Use and Misuse, 2022, 57, 1144-1153.	1.4	21
14	A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD). Journal of Medical Toxicology, 2022, , 1.	1.5	0
16	Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada. Drug and Alcohol Dependence, 2022, 241, 109544.	3.2	8
17	User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial. BMJ, The, 0, , e069271.	6.0	11
18	Multisite learning of high-dimensional heterogeneous data with applications to opioid use disorder study of 15,000 patients across 5 clinical sites. Scientific Reports, 2022, 12, .	3.3	0
19	Illicit Substance Use and the COVID-19 Pandemic in the United States: A Scoping Review and Characterization of Research Evidence in Unprecedented Times. International Journal of Environmental Research and Public Health. 2022, 19, 8883.	2.6	5

#	Article	IF	CITATIONS
20	The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder. Addiction Science & amp; Clinical Practice, 2022, 17, .	2.6	2
21	No Health without Mental Health: Taking Action to Heal a World in Distress—With People, Places, and Planet â€~in Mind'. Challenges, 2022, 13, 37.	1.7	5
22	The Association of the First Surge of the COVID-19 Pandemic with the High- and Low-Value Outpatient Care Delivered to Adults in the USA. Journal of General Internal Medicine, 2022, 37, 3979-3988.	2.6	2
23	Demographic Trends in Emergency Department Visits for Psychiatric Concerns During the COVID-19 Pandemic. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 436-442.	2.4	1
24	Under-representation of key demographic groups in opioid use disorder trials. , 2022, 4, 100084.		3
25	Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence, 2022, 239, 109609.	3.2	3
26	Factors related to substance use treatment attendance after peer recovery coach intervention in the emergency department. , 2022, 5, 100093.		5
27	Hepatitis C active viremia over time in an <scp>ED</scp> â€based testing programme: Impact, disparities and surveillance tool. Journal of Viral Hepatitis, 2022, 29, 1026-1034.	2.0	3
28	Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 2022, 143, 108896.	2.8	6
29	Community Initiated Care: A blue-print for the practical realization of contextual behavioral science. Journal of Contextual Behavioral Science, 2023, 27, 54-60.	2.6	2
30	Estimating County-Level Overdose Rates Using Opioid-Related Twitter Data: Interdisciplinary Infodemiology Study. JMIR Formative Research, 0, 7, e42162.	1.4	2
31	Prescription Opioid Use among Patients with Chronic Noncancer Pain before and after the COVID-19 Outbreak in Taiwan: A Multicenter Prospective Observational Study. Healthcare (Switzerland), 2022, 10, 2460.	2.0	0
32	Nonfatal opioid-related overdoses treated by emergency medical services in Florida, before and during the COVID-19 pandemic. Preventive Medicine Reports, 2023, 31, 102102.	1.8	1
33	Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. Journal of General Internal Medicine, 2023, 38, 733-737.	2.6	5
34	The salience of social context, opioid antagonist use, and prior opioid exposure as determinants of fatal and non-fatal opioid overdoses. Health and Place, 2023, 79, 102970.	3.3	0
35	Exploring county-level spatio-temporal patterns in opioid overdose related emergency department visits. PLoS ONE, 2022, 17, e0269509.	2.5	5
36	Racial and Ethnic Disparities in Emergency <scp>Departmentâ€Initiated</scp> Buprenorphine Across 5 Healthcare Systems. Academic Emergency Medicine, 0, , .	1.8	1
39	Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder. JAMA Network Open, 2023, 6, e235439.	5.9	11

CITATION REPORT

#	Article	IF	CITATIONS
40	Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series. , 2023, 7, 100144.		0
41	Experiences of patients at high risk of opioid overdose accessing emergency department and behavioral health interventions: a qualitative analysis in an urban emergency department. BMC Health Services Research, 2023, 23, .	2.2	1
42	Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico. Addiction Science & Clinical Practice, 2023, 18, .	2.6	1
43	Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic. Journal of Addiction Medicine, 2023, 17, e172-e176.	2.6	Ο
44	Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation. Harm Reduction Journal, 2023, 20, .	3.2	4
45	The COVIDâ€19 impact and characterization on substance useâ€related emergency department visits for adolescents and young adults in Canada: Practical implications. Journal of Evaluation in Clinical Practice, 2023, 29, 447-458.	1.8	0
46	Patterns of opioid use behaviors among patients seen in the emergency department: Latent class analysis of baseline data from the POINT pragmatic trial. , 2023, 146, 208979.		2
47	Emergency Department-Initiated Buprenorphine Treatment in a Population with a High Rate of Homelessness: An Observational Study. Journal of Emergency Medicine, 2023, 64, 129-135.	0.7	0
48	COVID-19 impact on opioid overdose after jail release in Massachusetts. , 2023, 6, 100141.		1
49	Increases in overdoses during the COVID-19 pandemic. Baylor University Medical Center Proceedings, 2023, 36, 411-412.	0.5	1
50	Evaluating disparities by social determinants in hospital admission decisions for patients with COVID-19 quaternary hospital early in the pandemic. Medicine (United States), 2023, 102, e33178.	1.0	0
51	Interrupted Time Series Analysis: Patient Characteristics and Rates of Opioid-Use-Disorder-Related Emergency Department Visits in the Los Angeles County Public Hospital System during COVID-19. Healthcare (Switzerland), 2023, 11, 979.	2.0	Ο
52	METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES. Journal of Emergency Medicine, 2023, 64, 391-396.	0.7	1
53	Implementation strategies to address the determinants of adoption, implementation, and maintenance of a clinical decision support tool for emergency department buprenorphine initiation: a qualitative study. Implementation Science Communications, 2023, 4, .	2.2	1
54	The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose. , 2023, 152, 209103.		5
55	Social vulnerability predictors of drug poisoning mortality: A machine learning analysis in the United States. American Journal on Addictions, 2023, 32, 539-546.	1.4	1
56	Educational training to improve opioid overdose response among health center staff: a quality improvement initiative. Harm Reduction Journal, 2023, 20, .	3.2	1
58	Substance Use Disorders in Adolescents and Young Adults: History and Perioperative Considerations From the Society for Pediatric Pain Medicine. Anesthesia and Analgesia, 0, , .	2.2	О

CITATION REPORT

#	Article	IF	CITATIONS
59	An interrupted time series analysis of trends in opioid-related emergency department visits from pre-COVID-19 pandemic to pandemic, from the Canadian Hospitals Injury Reporting and Prevention Program. BMC Public Health, 2023, 23, .	2.9	0
60	Behavioral Health Decision Support Systems and User Interface Design in the Emergency Department. Applied Clinical Informatics, 2023, 14, 705-713.	1.7	0
61	Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder. Annals of Emergency Medicine, 2023, 82, 694-704.	0.6	0
62	Rapid Methadone Induction in a General Hospital Setting: A Retrospective, Observational Analysis. Substance Abuse, 2023, 44, 177-183.	2.3	1
63	Trends in Non-Fatal and Fatal Opioid Overdoses During the First Two Years of the Coronavirus Disease-2019 Pandemic. Annals of Epidemiology, 2023, , .	1.9	0
64	Acute care pathway assessed through performance indicators during the COVID-19 pandemic in OECD countries (2020–2021): a scoping review. BMC Emergency Medicine, 2024, 24, .	1.9	0
65	An interpretable machine learning framework for opioid overdose surveillance from emergency medical services records. PLoS ONE, 2024, 19, e0292170.	2.5	0
66	Alignment of substance use community benefit prioritization and service lines in US hospitals: a cross-sectional study. Addiction Science & Clinical Practice, 2024, 19, .	2.6	0
67	A qualitative assessment of emergency physicians' experiences with robust emergency department buprenorphine bridge programs. Academic Emergency Medicine, 0, , .	1.8	0
68	Nurse-focused ultrasound-guided IV program improves core emergency department process measures. Journal of Vascular Access, 0, , .	0.9	0
69	"lt gets you high as a kite but not unsick― Characterizations of and responses to a changing local drug supply by people who use drugs in Rhode Island. International Journal of Drug Policy, 2024, 127, 104391.	3.3	0
70	Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis. International Journal of Drug Policy. 2024, 127, 104392.	3.3	0